Abstract
Background: Diabetes is worldwide a major health issue; in 2019 there are 463 million people with Diabetes and models expect that these numbers rise till 578 million for the year 2030 and 700 million for the year 2045. Metformin is a well-recognised effective drug in the treatment of diabetes and prediabetes as well as other symptoms of insulin resistance. Due to metformin’s safety profile, the low costs, weight loss and cardiovascular benefits metformin has been selected as the first line drug in several major guidelines.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
